Patrick Verschueren

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby, Patrick Durez, Maya H Buch et al. · The Lancet · 2021 · 315 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Felice Rivellese, Anna E. A. Surace, Katriona Goldmann et al. · Nature Medicine · 2022 · 279 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Technical and Diagnostic Performance of 6 Assays for the Measurement of Citrullinated Protein/Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis

Dries Coenen, Patrick Verschueren, René Westhovens et al. · Clinical Chemistry · 2007 · 171 citations · Full text

Life Sciences, Clinical Sciences, Internal Medicine +17

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

Kim Lauper, Michele Iudici, Denis Mongin et al. · Annals of the Rheumatic Diseases · 2022 · 145 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13